RxDoctor Payments Data

Shellie Hardcastle, APRN

Family · Bowling Green, KYNPI 1033111901

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,395 of the $14,969 with a category attached, or 82.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,969in general payments, 2019–2025

Across 633 payments — averaging $23.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Pfizer$803
  • Seagen Inc.$759
  • Daiichi Sankyo Inc.$742
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,39583%
  • Education$1,3119%
  • Other$1,2638%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis73$2,377
AstraZeneca(2 entities)50$1,418
Johnson & Johnson43$1,005
Pfizer53$803
Seagen Inc.20$759
Daiichi Sankyo Inc.30$742
Bristol Myers Squibb30$561
E.r. Squibb & Sons, L.L.C.28$531
Merck26$449
Genentech USA, Inc.19$399
Sanofi13$323
Gilead13$312
Exelixis Inc.13$298
Regeneron Healthcare Solutions, Inc.11$282
AbbVie9$280
Incyte Corporation10$248
Pharmacyclics LLC, An Abbvie Company10$234
Amgen11$222
Beigene USA, Inc.3$184
Coherus Oncology, Inc.9$173
Lilly USA, LLC9$166
Eisai Inc.8$163
Angiodynamics, Inc.2$141
AVEO Pharmaceuticals, Inc.6$140
Progenics Pharmaceuticals, Inc.2$139
Taiho Oncology, Inc.6$131
Beone Medicines USA, Inc.3$126
Astellas Pharma US Inc6$124
Takeda Pharmaceuticals U.S.A., Inc.5$111
Stemline Therapeutics Inc.5$105
Genmab U.S., Inc.4$97
Array Biopharma Inc9$94
Bayer6$94
EMD Serono, Inc.3$91
ADC Therapeutics America, Inc.5$91
Pharmacosmos Therapeutics Inc.5$87
Boehringer Ingelheim4$86
Karyopharm Therapeutics Inc.5$85
Ipsen Biopharmaceuticals, Inc5$81
Rigel Pharmaceuticals, Inc.4$79
Pharmaessentia USA Corporation4$78
Geron Corporation2$74
Sobi, Inc3$62
Kyowa Kirin, Inc.3$60
Blueprint Medicines Corporation3$60
Morphosys, US Inc.3$57
Azurity Pharmaceuticals, Inc.2$57
Tersera Therapeutics LLC2$56
Global Blood Therapeutics, Inc.3$52
Puma Biotechnology, Inc.3$47
G1 Therapeutics, Inc.2$44
Mirati Therapeutics, Inc.2$41
TG Therapeutics, Inc.2$40
GSK2$38
Myovant Sciences Inc.2$31
Apellis Pharmaceuticals, Inc.2$29
Novocure Inc.1$24
Dova Pharmaceuticals1$23
Alnylam Pharmaceuticals Inc.1$22
Accord Healthcare, Inc.1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,969 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$8,332
Medicare patients
71
Services billed
107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate11$278,690
TasignaNilotinib Hcl12$247,713
ImbruvicaIbrutinib18$233,523
ErleadaApalutamide13$189,292
CalquenceAcalabrutinib Maleate11$169,663
EliquisApixaban39$30,705
XareltoRivaroxaban27$14,623
Ondansetron OdtOndansetron100$1,943
Prochlorperazine Maleate30$590
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine28$530
Anastrozole45$478
Dexamethasone19$355
Letrozole26$310
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$253
Warfarin Sodium71$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$298$278,69011 claims
NovartisTasigna$2,377$247,71312 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$234$233,52318 claims
Johnson & JohnsonErleada, Xarelto$1,005$203,91540 claims
AstraZenecaCalquence$1,418$169,66311 claims
PfizerEliquis$803$30,70539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.

Other family in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →